Search
Entera Bio Ltd
ENTXAdd to Watchlist
1.660USD
-0.030-1.78%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
77.39MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Entera Bio Ltd is 8.00, ranking 166 out of 387 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 10.00 and a low of 10.00.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
9.000
Target Price
+445.45%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Entera Bio Ltd
ENTX
1
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Entera Bio Ltd's price target?
Analysts forecast that Entera Bio Ltd's price target is USD 10.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 10.00.
How have Entera Bio LtdENTX's recent earnings per share performed?
The market expectation was USD -0.07, while Entera Bio LtdENTX's earnings per share (EPS) for the previous quarter was USD -0.06. EPS for the next quarter is expected at USD -0.08.
What is the analyst rating for Entera Bio Ltd?
Based on the ratings of Entera Bio Ltd's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.